A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

NCT00878709 ·Status: COMPLETED ·Phase: PHASE3

An Observational Study of Avastin (Bevacizumab) in Patients With HER2-metastatic or Locally Advanced Breast Cancer

NCT01461044 ·Status: COMPLETED

Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer

NCT05912062 ·Status: UNKNOWN

Safety, Effectiveness and Quality of Life of Trastuzumab Deruxtecan in Patients with HER2+ Breast Cancer

NCT05149014 ·Status: COMPLETED

Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer

NCT03433313 ·Status: COMPLETED ·Phase: PHASE3

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

NCT01953926 ·Status: TERMINATED ·Phase: PHASE2

Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer

NCT00300781 ·Status: COMPLETED ·Phase: PHASE2

Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France

NCT05697146 ·Status: ACTIVE_NOT_RECRUITING

DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer

NCT05334810 ·Status: UNKNOWN ·Phase: PHASE2

Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

NCT00371345 ·Status: COMPLETED ·Phase: PHASE2

Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

NCT03393845 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer

NCT00915018 ·Status: COMPLETED ·Phase: PHASE2

Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies

NCT03390894 ·Status: RECRUITING

Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer

NCT05154396 ·Status: UNKNOWN ·Phase: PHASE2

A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

NCT05911958 ·Status: RECRUITING ·Phase: PHASE2

Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer

NCT04460430 ·Status: TERMINATED ·Phase: PHASE2

Study of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Participants With Early/Metastatic Breast Cancer in Saudi Arabia

NCT02954471 ·Status: COMPLETED

Pyrotinib in HER2-positive Early Breast Cancer

NCT06718335 ·Status: NOT_YET_RECRUITING ·Phase: NA

Pyrotinib in Women With High-risk in Early Stage Breast Cancer

NCT05834764 ·Status: RECRUITING ·Phase: PHASE2

Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer

NCT05569187 ·Status: COMPLETED

Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer

NCT07333937 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy

NCT05853432 ·Status: COMPLETED

Fulvestrant + Neratinib In Breast Cancer

NCT04901299 ·Status: WITHDRAWN ·Phase: PHASE2

A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

NCT06954961 ·Status: RECRUITING ·Phase: PHASE3

An Observational Study on Human Epidermal Growth Factor Receptor (HER) 2 Status of Breast Invasive Carcinoma in Latin American Participants

NCT02535026 ·Status: COMPLETED